Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Engelman
Alan Engelman, Brookline, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110142854 | COMPOSITIONS AND METHODS FOR INHIBITION OF RETROVIRUSES - Described herein are methods and compositions for the inhibition of retroviral integration and replication. The methods and compositions inhibit the activity of one or more components of the SET complex or base excision repair enzymes and induce autointegration of retroviral double-stranded nucleic acid. | 06-16-2011 |
Donald Engelman, Guilford, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20090298761 | Methods of treating cartilage defects using a soluble morphogenic protein complex - The present invention provides methods of repairing and regenerating cartilage tissue using a soluble morphogenic protein complex comprising (a) a morphogenic protein; and (b) a morphogenic protein pro region isolated from a morphogenic protein, or a conservative substitution variant or a fragment of said pro region, wherein said pro region or variant or fragment is noncovalently linked to the morphogenic protein, and wherein said complex is more soluble in an aqueous solvent than said morphogenic protein alone. | 12-03-2009 |
Donald M. Engelman, New Haven, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20120039990 | Liposome Compositions and Methods of Use Thereof - The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide. | 02-16-2012 |
Donald M. Engelman, Guilford, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20090048555 | DRUG DELIVERY SYSTEM - A drug delivery system including a chamber, which is configured for enclosing or covering at least a surface of a patient, a source of a drug and a pressure source, which selectively pressurizes the chamber. In addition, the system includes a controller for controlling the transfer of the drug to the chamber wherein the drug is administered to the surface of the patient under pressure. | 02-19-2009 |
E. Eric Engelman, Doylestown, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20110243860 | ORAL CARE COMPOSITIONS - Oral care compositions that are stable, pourable and swishable suspension containing suspending polymer(s). Optional further components include abrasives, surfactants, flavorings, colorings, anti-plaque agents, anti-tartar agents, agents for sensitive teeth, fluoride ion sources and sweeteners. | 10-06-2011 |
| 20110243861 | ORAL CARE COMPOSITIONS - The present invention relates generally to oral care compositions, and more specifically to oral care compositions suitable for cleaning the oral cavity. Methods of use are also disclosed. | 10-06-2011 |
Jeffery A. Engelman, Mead, CO US
| Patent application number | Description | Published |
|---|---|---|
| 20090015856 | METHODS AND STRUCTURE FOR MANAGING PRESENTATION OF MULTI-LANGUAGE FONTS - Methods and structures for improved font management providing for selection of one or more subsets of a selected typeface font in a font management program. A user is presented with information identifying one or more subsets of related code points in a selected typeface in a font management program. By selecting one or more subsets from the presented information, the user may reduce wasted presentation or management of code points in the typeface that are not presently of interest to the user. For example, when managing a Unicode typeface, a user may be prompted to select one or more language subsets prior to printing/displaying a matrix of the glyphs of the selected typeface. The presentation of glyphs or other code point information may then be limited to only the selected one or more subsets. | 01-15-2009 |
Lawrence Engelman, Oxford, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20080215376 | LONG-TERM CARE INSURANCE - An insurance policy in which the initial maximum benefit payable under the policy is less than or equal to the premium. The policy protects an insured's assets under a Government benefit program that has an asset limit for applicants and that allows applicants to shelter assets by obtaining private insurance. Assets may be sheltered under such a Government program by providing such insurance, obtaining payment for a benefit under the insurance; and applying benefits under the Government program. Insurance can be sold to shelter assets under such a Government benefit program by setting the maximum payable benefit to less than or equal to the premium. Optionally, the initial maximum benefit payable under the policy is less than or equal to about 105% of the premium. The Government benefit program may be a Medicaid State Long-Term Care (LTC) Partnership Program and the insurance benefit may be a long-term health care benefit. | 09-04-2008 |
Robert W. Engelman, Tampa, FL US
| Patent application number | Description | Published |
|---|---|---|
| 20080280812 | HUMAN IMMUNOSUPPRESSIVE PROTEIN - A method for purifying an immunosuppressant protein (HISP) has the steps of obtaining supernatant from hNT cells; exposing the supernatant to preparative polyacrylamide gel electrophoresis to produce 20 isoelectric fractions, including active isoelectric fraction #10; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting the free fraction containing the concentrated, isolated HISP. Also disclosed is a method of treating inflammation, using an effective amount of an HISP. The HISP is anionic, has a molecular weight of 40-100 kDa, an isoelectric point of about 4.8 and is obtained from the supernatant of hNT cells, but not from NCCIT embryonal carcinoma cells. T98G glioblastoma cells or THP-1 monocytic leukemia cells. HISP can maintain T cells in a quiescent G.sub.0/G.sub.1 state without lowering their viability. HISP loses activity when treated with heat, pH2, pH11, or mixed with trypsin or carboxypeptidase, but not with neuraminidase. HISP can suppress proliferation of responder peripheral blood mononuclear cells in allogeneic mixed lymphocyte cultures; HISP can suppress T-cell proliferation and IL-2 production in response to phorbol 12-myristate 13-acetate (PMA), ionomycin and concanavalin-A. HISP does not bind to heparin-sepharose CL-B gel; or to albumin-binding resin Blue Sepharose, HISP is concentrated with YM10 ultrafiltration. HISP does not act through the T-cell receptor-CD3 complex or via altered accessory signal cells. A method of treating inflammation comprises administering an effective amount of hNT neuronal cells. | 11-13-2008 |